检验医学与临床2018，Vol.15Issue(9)：1228-1231,4.DOI:10.3969/j.issn.1672-9455.2018.09.004
21基因RS在早期乳腺癌治疗决策中的应用研究
Application of 21-gene Recurrence Score in therapeutic decision-making for early breast cancer
摘要
Abstract
Objective To investigate the correlation between 21-gene Recurrence Score(RS)and clinic pathological features and the effect of RS on treatment programme making in the early breast cancer patients with estrogen receptor(ER)positive,lymph node negative and human epidermal grow th factor receptor (HER)2 negative.Methods The expression levels of TUBB3,TYMS,TOP2A and 21 genes in 120 cases of breast cancer tissue detected by branch-DNA liquid chip technology.The relationship between the expression of the above 21-gene RS and the clinical and pathological characteristics of breast cancer were analyzed.Devel-op treatment protocols based on the RS score and mRNA expression.Results Among the 120 patients,61.7%had a low RS that less than 18 scores,26.7% had an intermediate RS that from 18 to less than 31 scores,and 11.7% had a high RS that equal or more than 31 scores.Cases with RS stases on different characteristics of histological grade,progesterone receptor(PR)and Ki-67 were statistically different(P<0.05).Treatment de-cisions were changed in 51.6% patients in 120 patients.48.3% patients avoided chemotherapy.The median follow-up time was 22 months.Only 3 cases had recurrence.No distal metastasis was reported.Conclusion The 21-gene RS is closely related to the histological grade,PR and Ki-67,RS reduces chemotherapy use in ear-ly breast cancer patients.关键词
乳腺癌/21基因复发评分/化疗Key words
breast cancer/21-gene Recurrence Score/chemotherapy分类
医药卫生引用本文复制引用
卢卫国,何伟业,谢在春..21基因RS在早期乳腺癌治疗决策中的应用研究[J].检验医学与临床,2018,15(9):1228-1231,4.基金项目
广东省中医药局建设中医药强省科研项目(20151194). （20151194）
